

Beth Israel Lahey Health GLP-1RA Conversion Guide

11/2022

The purpose of this guide is to assist with the conversion of GLP1-RA's due to current product shortages. Assessment of equivalent dose is based on head-to-head clinical trials when available and/or clinical experience. This guide does not replace clinical judgment.

Drug	Frequency	Equivalent Dose (A1c Reduction)				
Dulaglutide (Trulicity)¹	Weekly		0.75 mg	1.5 mg	3 mg ⁴	4.5 mg ⁴
Semaglutide (Ozempic)¹	Weekly	0.25 mg ²		0.5 mg	1 mg	2 mg
Liraglutide (Victoza)¹	Daily	0.6 mg ²	1.2 mg	1.8 mg		
Oral Semaglutide (Rybelsus)	Daily	3 mg ²	7 mg	14 mg		
Exenatide (Bydureon BCise) ³	Weekly		2 mg ³			
Exenatide (Byetta) <i>Rarely used, not recommended to initiate</i>	Twice Daily	5 mcg	10 mcg			
Tirzepatide (Mounjaro)	Given novel mechanism (GIP/GLP1), consider starting at initiation dose of 2.5 mg ² once weekly x 4 weeks, then increase to 5 mg once weekly. Continue to increase by 2.5 mg increments every 4 weeks as tolerated for additional glycemic control. <i>Not currently indicated for ASCVD risk reduction.</i>					

¹ Agents with ASCVD evidence in bold


² Starting doses not considered therapeutic. Increase dose after indicated duration, if tolerating.

³ Increased risk of injection site reactions vs. Trulicity, Ozempic, and Victoza.

⁴ Additional A1c reduction not as significant as weight reduction at higher doses

Northeast

Physician Hospital Organization



Last updated 11/30/2022

Northeast

Physician Hospital Organization

Summary of Clinical Evidence and Comparison Chart

Trial	Active Comparators	Background Regimen	Time Point for efficacy, weeks	A1c reduction	Weight loss, kg	Adverse Effects: D/C due to GI adverse events
Award 11	Trulicity 1.5 mg vs. Trulicity 3 mg	Metformin	36	Trulicity 1.5 mg: -1.5% Trulicity 3 mg: -1.6% not statistically sig	-8.4 lbs (3 mg)	3.1%
Award 11	Trulicity 1.5 mg vs. Trulicity 4.5 mg	Metformin	36	Trulicity 4.5 mg: -1.8% P < 0.001	-10.1 lbs (4.5 mg)	3.1%
SUSTAIN 7	Ozempic 1 mg vs. Trulicity 1.5 mg	Metformin	40	Ozempic 1 mg: -1.6% Trulicity 1.5 mg: -1.3% p=0.0004	Ozempic 1 mg: -12.8 lbs Trulicity 1.5 mg: -6.2 lbs	6% (vs. 5% Trulicity)
SUSTAIN FORTE	Ozempic 1 mg vs. Ozempic 2 mg	Metformin +/- SFU	40	Ozempic 1 mg: -1.9% Ozempic 2 mg: -2.1% P < 0.01	Ozempic 2 mg: -14.2 lbs Ozempic 1 mg: -12.5 lbs	Not documented. Nausea 14% vs. 15%
SURPASS-2	Ozempic 1 mg vs. Mounjaro 5 mg, 10 mg, 15 mg	Metformin	40	Mounjaro 5 mg: -2% Mounjaro 10 mg: -2.2% Mounjaro 15 mg: -2.3% Ozempic 1 mg: -1.9%	Mounjaro 5 mg: -17 lbs Mounjaro 10 mg: -21 lbs Mounjaro 15 mg: -25 lbs Ozempic 1 mg: -13 lbs	Mounjaro 5 mg: 2.8% Mounjaro 10 mg: 4.3% Mounjaro 15 mg: 4.3% Ozempic 1 mg: 3.2%

Northeast

Physician Hospital Organization

References:

- Almandoz J, Lingvay I, Morales J et al. Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. *Clin Diabetes*. 2020; 38 (4):390-402.
 - Frías, Juan P., et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). *Diabetes Care*. 2021; 44(3): 765-773.
 - Pratley RE, Aroda VR, Lingvay I, et al, on behalf of the SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*. 2018;6(4):275-286.
 - Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*. 2021;9(9):563-574.
 - Frías JP, Davies MJ, Rosenstock J, et al.; for the SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med*. 2021;385(6 suppl):503-515
-